{"meta":{"query_hash":"c3179db2e965","filters":{"venue":"Immuno-Oncology Technology"},"cohort_total":41,"direct_labels_cover":0,"predictions_cover":41,"exported":41,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/c3179db2e965","api":"https://metacan.xera.ac/api/v1/cohort?venue=Immuno-Oncology+Technology"},"results":[{"id":"W4310923624","doi":"10.1016/j.iotech.2022.100230","title":"241P Treatment and outcomes of patients with gastrointestinal toxicity following immunotherapy: A large multi-center retrospective study in the United Kingdom by the National Oncology Trainees Collaborative for Healthcare Research (NOTCH)","year":2022,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Center (category theory); Retrospective cohort study; Health care; Immunotherapy; Toxicity; Internal medicine; Family medicine; Oncology; Cancer; Political science","score_opus":0.059524769806824473,"score_gpt":0.4100764466070851,"score_spread":0.3505516768002606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310923624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97745794,0.0005127418,0.000050132636,0.01653739,0.0001005449,0.004785206,0.0004837496,0.000040577434,0.000031690382],"genre_scores_gemma":[0.9956472,0.00003170942,0.000522679,0.00095883274,0.000012514066,0.0026161452,0.00013933865,0.000029622079,0.000041950672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690294,0.0011132029,0.0005441201,0.0004439576,0.00045122887,0.0005445197],"domain_scores_gemma":[0.99783516,0.0009162865,0.00030205384,0.0003361015,0.0005841107,0.000026267575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023047007,0.00025528178,0.00071103085,0.0006750862,0.000734471,0.000012469387,0.00038663286,0.00015371088,0.00002332439],"category_scores_gemma":[0.00029290043,0.00014911685,0.000107868094,0.0016632746,0.00070527307,0.00004545688,0.00014316376,0.0007383948,2.3652817e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013705742,0.012585397,0.95196277,0.000011813362,0.0010382478,0.000031752523,0.01209001,0.0000021428573,0.004977296,0.00038831585,0.00033652366,0.0028699993],"study_design_scores_gemma":[0.083937384,0.08567607,0.712142,0.00004722605,0.00011122094,0.00018765718,0.08705856,0.00006083765,0.00032208912,0.00024164244,0.02997163,0.00024368253],"about_ca_topic_score_codex":0.0007352727,"about_ca_topic_score_gemma":0.0018862323,"teacher_disagreement_score":0.23982075,"about_ca_system_score_codex":0.0025083704,"about_ca_system_score_gemma":0.0007807809,"threshold_uncertainty_score":0.65593016},"labels":[],"label_agreement":null},{"id":"W4310923924","doi":"10.1016/j.iotech.2022.100213","title":"109P Impact of anti-drug antibody (ADA) on naxitamab efficacy and safety","year":2022,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Drug; Medicine; Pharmacology","score_opus":0.014692821784628659,"score_gpt":0.3674672308365919,"score_spread":0.3527744090519632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310923924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98097336,0.003052603,0.000007889607,0.009405547,0.00022742798,0.00060741743,0.00009124161,0.00014807448,0.0054864353],"genre_scores_gemma":[0.996873,0.001079869,0.00029230566,0.00026699874,0.000053065116,0.0000495478,0.000092058945,0.000035415338,0.0012577444],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997735,0.00020379959,0.0005361369,0.00048578013,0.00040279137,0.0006364514],"domain_scores_gemma":[0.9985066,0.0004377074,0.00020779094,0.0006057084,0.00012865604,0.000113547874],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054288894,0.0002816277,0.0009294445,0.0008908773,0.0004046449,0.0000055888154,0.00042374714,0.00028561417,0.0010703525],"category_scores_gemma":[0.00021256336,0.00023029184,0.00020901005,0.0008125411,0.0010476558,0.000039383627,0.00080944074,0.0012341536,0.0000394124],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012026061,0.003125018,0.17325127,0.00014248065,0.0013675955,0.0012918484,0.00057025754,0.000064782536,0.6996212,0.012073907,0.0064884056,0.08997716],"study_design_scores_gemma":[0.016727379,0.033861678,0.61450124,0.00013895369,0.0002510625,0.007032992,0.0014665487,0.00030390007,0.028844232,0.0021759951,0.29394266,0.0007533955],"about_ca_topic_score_codex":0.00024346076,"about_ca_topic_score_gemma":0.000006818613,"teacher_disagreement_score":0.67077696,"about_ca_system_score_codex":0.00036197747,"about_ca_system_score_gemma":0.00050186546,"threshold_uncertainty_score":0.9998428},"labels":[],"label_agreement":null},{"id":"W4311139822","doi":"10.1016/j.iotech.2022.100303","title":"191P Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy and combination with checkpoint inhibitors in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors","year":2022,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Pharmacodynamics; Immunotherapy; Peripheral blood mononuclear cell; Cancer; Antigen; Immunology; Pharmacokinetics","score_opus":0.007143621557407641,"score_gpt":0.27518211663172687,"score_spread":0.2680384950743192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311139822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99535185,0.002689352,0.000022586155,0.00048169732,0.00004551518,0.0011204334,0.00011982475,0.000016122623,0.00015260135],"genre_scores_gemma":[0.997711,0.0007707746,0.0005650522,0.000035227695,0.0000029850207,0.00046902391,0.00034331216,0.000028946164,0.000073666146],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99819994,0.00019131476,0.0005075209,0.0005578337,0.000169537,0.0003738362],"domain_scores_gemma":[0.999178,0.000053123364,0.00029842465,0.00033542045,0.00008542671,0.000049619677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029630322,0.00023639748,0.00042460865,0.00044323844,0.00011408933,0.0000053017397,0.00018265194,0.00015569403,0.000015623991],"category_scores_gemma":[0.00007111226,0.00018858204,0.000026711778,0.0005046342,0.0005826889,0.000014546617,0.00043179622,0.00025605943,3.939684e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26306385,0.0050458796,0.24825077,0.00015368959,0.00073155016,0.0004776891,0.0009478804,0.0002834555,0.09538902,0.00007039359,0.00043790633,0.3851479],"study_design_scores_gemma":[0.17495345,0.17147124,0.45751646,0.0003688645,0.00012944956,0.00083770044,0.003581956,0.0003840369,0.16546728,0.0009047493,0.022905938,0.0014788714],"about_ca_topic_score_codex":0.00020970342,"about_ca_topic_score_gemma":0.0025217743,"teacher_disagreement_score":0.38366905,"about_ca_system_score_codex":0.0003180745,"about_ca_system_score_gemma":0.00030034367,"threshold_uncertainty_score":0.76901525},"labels":[],"label_agreement":null},{"id":"W4389480655","doi":"10.1016/j.iotech.2023.100692","title":"LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Symphogen; Astellas Pharma; Gilead Sciences; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Durvalumab; Internal medicine; Neutropenia; Gastroenterology; Etoposide; Cancer; Chemotherapy; Immunotherapy; Pembrolizumab","score_opus":0.032707548856386964,"score_gpt":0.3655740603058458,"score_spread":0.3328665114494589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389480655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9694259,0.001539929,0.00010970466,0.018765852,0.0006614402,0.006933155,0.000986919,0.0009387322,0.00063833315],"genre_scores_gemma":[0.989993,0.0012126926,0.0013843937,0.00080390525,0.00027670155,0.002945234,0.0007750448,0.00013632324,0.0024727504],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99533457,0.00021286431,0.0010941239,0.0013326522,0.00069743086,0.0013283788],"domain_scores_gemma":[0.993718,0.0025326167,0.00060467276,0.0019964173,0.0010294064,0.00011884997],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010139317,0.00060026255,0.0014364887,0.0004714144,0.00090659084,0.000029871419,0.00097158446,0.0005695614,0.000041312647],"category_scores_gemma":[0.0042388258,0.00041371866,0.00016806142,0.0017036416,0.0017076109,0.00015371622,0.0010487156,0.0011325612,0.0001251026],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12016451,0.021354057,0.28777644,0.00073612307,0.009339417,0.0060652373,0.017616883,0.0001650356,0.02358657,0.00064366224,0.15604195,0.3565101],"study_design_scores_gemma":[0.20952213,0.08438363,0.31387997,0.00095873233,0.0014108345,0.00016876133,0.013842349,0.00069930987,0.006390626,0.001124041,0.3661595,0.0014601243],"about_ca_topic_score_codex":0.0004993032,"about_ca_topic_score_gemma":0.0016075599,"teacher_disagreement_score":0.35504997,"about_ca_system_score_codex":0.0011286214,"about_ca_system_score_gemma":0.00074711704,"threshold_uncertainty_score":0.99983144},"labels":[],"label_agreement":null},{"id":"W4389480683","doi":"10.1016/j.iotech.2023.100693","title":"LBA3 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic NSCLC (mNSCLC): 5-year (y) overall survival (OS) update from the POSEIDON study","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Internal medicine; Durvalumab; Regimen; Chemotherapy; Gastroenterology; Progression-free survival; Nuclear medicine; Confidence interval; Oncology; Immunotherapy; Pembrolizumab; Cancer","score_opus":0.025379405179619445,"score_gpt":0.3139009496148696,"score_spread":0.28852154443525013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389480683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95097107,0.0036162017,0.00004327789,0.0403178,0.0013715292,0.002250215,0.000069446956,0.0008400572,0.0005204048],"genre_scores_gemma":[0.9919168,0.0046182442,0.00030337812,0.0016923987,0.00017737281,0.00044778624,0.00018843738,0.0001338703,0.00052174466],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995767,0.000464225,0.0012077213,0.0009952752,0.0004938462,0.0010719132],"domain_scores_gemma":[0.99683475,0.00082676933,0.00039172056,0.0017228685,0.00014201872,0.00008184253],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016124569,0.0006060202,0.0014191103,0.00089810725,0.0003158675,0.000039410523,0.0010493473,0.0004411705,0.001198363],"category_scores_gemma":[0.00033185625,0.00046450866,0.00031526963,0.0024387885,0.00076021964,0.00013100024,0.00034831985,0.0011556677,0.00045661503],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053025354,0.011500419,0.2505793,0.00014103147,0.010332306,0.006113156,0.006473698,0.00013667702,0.12208988,0.0018678268,0.022494433,0.5152459],"study_design_scores_gemma":[0.14325523,0.012354636,0.4292913,0.00045860646,0.001171693,0.0006990294,0.018726792,0.00084399333,0.008427606,0.009391535,0.3734807,0.0018988689],"about_ca_topic_score_codex":0.0025711185,"about_ca_topic_score_gemma":0.0060787974,"teacher_disagreement_score":0.513347,"about_ca_system_score_codex":0.0008040701,"about_ca_system_score_gemma":0.00048521018,"threshold_uncertainty_score":0.99978065},"labels":[],"label_agreement":null},{"id":"W4389480748","doi":"10.1016/j.iotech.2023.100601","title":"129P Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Refractory (planetary science); Neuroblastoma; Internal medicine; Population; Bone marrow; Phases of clinical research; Interim analysis; Oncology; Nuclear medicine; Gastroenterology; Clinical trial","score_opus":0.0071836360981520995,"score_gpt":0.2752357812312524,"score_spread":0.26805214513310033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389480748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463046,0.0004657304,0.0000045900656,0.002426938,0.00016300408,0.0013389013,0.00010771002,0.00068094477,0.00018172221],"genre_scores_gemma":[0.9980025,0.0005363307,0.00028483194,0.00019224558,0.000016500404,0.00025304913,0.0002955566,0.00009380177,0.00032514698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968709,0.00029004735,0.0005302696,0.0008751633,0.00043049938,0.0010031582],"domain_scores_gemma":[0.99792117,0.0005912124,0.00028075158,0.0008108162,0.00018417848,0.00021184784],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026784095,0.0004473234,0.0009640403,0.0014931981,0.00020459916,0.000025377165,0.0002790366,0.0005404781,0.00009091944],"category_scores_gemma":[0.00097614137,0.0003634429,0.00007132353,0.0018971234,0.00086473214,0.00017104209,0.00035341398,0.0011398178,0.00028607383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019665012,0.016930584,0.66920227,0.00019153445,0.0020520315,0.013719898,0.00026409802,0.000011264563,0.08288424,0.0007455801,0.012494206,0.18183929],"study_design_scores_gemma":[0.06351068,0.046396885,0.84384906,0.00020552892,0.00044688515,0.00047533563,0.00023854613,0.0000239842,0.024283873,0.000684099,0.019274663,0.0006104706],"about_ca_topic_score_codex":0.00019894386,"about_ca_topic_score_gemma":0.00010795392,"teacher_disagreement_score":0.18122882,"about_ca_system_score_codex":0.0002661515,"about_ca_system_score_gemma":0.00034880074,"threshold_uncertainty_score":0.99988174},"labels":[],"label_agreement":null},{"id":"W4389480834","doi":"10.1016/j.iotech.2023.100668","title":"157TiP Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; Ipsen; Sanofi; Bayer HealthCare; F. Hoffmann-La Roche; Incyte; Natera; Amgen; ViiV Healthcare; Eisai; AstraZeneca; Bristol-Myers Squibb","keywords":"Pemetrexed; Pembrolizumab; Medicine; Lung cancer; Chemotherapy; Oncology; KRAS; Internal medicine; Lung; Cancer; Cisplatin; Colorectal cancer; Immunotherapy","score_opus":0.010848026459265988,"score_gpt":0.36124044456600973,"score_spread":0.35039241810674376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389480834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98927504,0.0032583189,0.000059045527,0.0023606543,0.00029877646,0.0034855113,0.000082734725,0.00046352617,0.00071642204],"genre_scores_gemma":[0.9959431,0.00081540534,0.00057693425,0.00020618096,0.000032649896,0.0015527338,0.00012621614,0.00009118772,0.0006555333],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997312,0.00010318112,0.00082063826,0.0007935146,0.00021797567,0.00075267977],"domain_scores_gemma":[0.9982427,0.00025684742,0.00041743062,0.0007527781,0.00022049632,0.00010978797],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020075469,0.000490348,0.0012656518,0.0016146121,0.00020864254,0.000008931451,0.00029553537,0.0005732311,0.00017204921],"category_scores_gemma":[0.00009090943,0.0004429165,0.000111754256,0.0022905516,0.00033011378,0.00008035707,0.00016098499,0.0005237858,0.0000068318204],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071839904,0.0134157855,0.5997234,0.0004642439,0.0020451443,0.0011637299,0.009420363,0.00036619525,0.22453882,0.0000689581,0.0012086899,0.14040066],"study_design_scores_gemma":[0.49134013,0.03997913,0.29105905,0.001073586,0.0038817308,0.00021087179,0.015713984,0.013734581,0.13579914,0.00023560571,0.005312706,0.0016594729],"about_ca_topic_score_codex":0.0009707676,"about_ca_topic_score_gemma":0.0009864597,"teacher_disagreement_score":0.48415616,"about_ca_system_score_codex":0.00085242547,"about_ca_system_score_gemma":0.00095355505,"threshold_uncertainty_score":0.99980223},"labels":[],"label_agreement":null},{"id":"W4389480868","doi":"10.1016/j.iotech.2023.100606","title":"134P A phase I study exploring the safety and tolerability of the small molecule PD-L1 inhibitor INCB099318 in select advanced solid tumors","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Incyte; Sierra Oncology; Da Volterra; Ipsen; Eisai; Bristol-Myers Squibb; AstraZeneca; Carrick Therapeutics; Pfizer; Dr. Falk Pharma; ViiV Healthcare","keywords":"Tolerability; Medicine; Pharmacokinetics; Internal medicine; Adverse effect; Clinical endpoint; Gastroenterology; Oncology; Pharmacology; Clinical trial","score_opus":0.04229348806635307,"score_gpt":0.3719076108827646,"score_spread":0.3296141228164115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389480868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896411,0.00043601845,0.000019703637,0.006397722,0.0002315331,0.0023354546,0.0000074600043,0.00017954112,0.00075150945],"genre_scores_gemma":[0.9982367,0.00034040332,0.00016736906,0.0001396978,0.000034369885,0.0008312867,0.000004920783,0.000028371476,0.00021686548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970971,0.0005526258,0.000916168,0.0005133659,0.00023427261,0.0006864879],"domain_scores_gemma":[0.99765116,0.00088804454,0.00023728219,0.0009804043,0.0001793369,0.00006378406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018819263,0.00025002757,0.0011896882,0.0005188298,0.00026710867,0.0000058582946,0.00053575775,0.00034212845,0.00003529602],"category_scores_gemma":[0.0019742032,0.0001589668,0.00009218289,0.0020650805,0.0014645257,0.000057597896,0.0008144485,0.0011338526,0.00001538231],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004831895,0.0032799882,0.77831143,0.00013089264,0.00041838497,0.00044668277,0.0056650033,0.000019889978,0.13829021,0.000507989,0.000104438725,0.06799319],"study_design_scores_gemma":[0.026746795,0.015803851,0.87786824,0.00029201517,0.00037174806,0.0005882822,0.027110547,0.0013446092,0.044289406,0.0018312138,0.0033315339,0.0004217736],"about_ca_topic_score_codex":0.00016254077,"about_ca_topic_score_gemma":0.00061931455,"teacher_disagreement_score":0.09955678,"about_ca_system_score_codex":0.00036625654,"about_ca_system_score_gemma":0.00066929444,"threshold_uncertainty_score":0.6482478},"labels":[],"label_agreement":null},{"id":"W4389480990","doi":"10.1016/j.iotech.2023.100488","title":"19P The prognostic value of soluble CD73 in advanced triple-negative breast cancer: An exploratory analysis of the SYNERGY trial","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Stichting Tegen Kanker","keywords":"Breast cancer; Oncology; Triple-negative breast cancer; Internal medicine; Value (mathematics); Exploratory analysis; Medicine; Cancer; Statistics; Mathematics; Computer science; Data science","score_opus":0.010884968383471838,"score_gpt":0.28946558515830495,"score_spread":0.2785806167748331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389480990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99560416,0.0018228213,0.000052549043,0.0013430978,0.00046864807,0.0005329492,0.000051182342,0.000037922375,0.00008668476],"genre_scores_gemma":[0.9986267,0.0005652246,0.00007135405,0.00008569244,0.00006737309,0.0003906703,0.00004461814,0.000020891399,0.00012747762],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982057,0.0003572754,0.0005655828,0.00038067444,0.00013507814,0.00035567436],"domain_scores_gemma":[0.9984444,0.00016557498,0.00043236068,0.000763283,0.00017030649,0.000024081557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005150388,0.00018929028,0.0005384994,0.0004592156,0.000107640764,0.000003932537,0.0008210902,0.0004780738,0.000026761396],"category_scores_gemma":[0.00035691148,0.00012929969,0.0001994193,0.002761916,0.0006740897,0.000009326687,0.00038933064,0.00026264047,0.0000013486457],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009796202,0.00078312506,0.04887722,0.000037015256,0.0029461533,0.000023570481,0.0012139216,0.02013448,0.89843243,0.0024804082,0.0016661948,0.013609247],"study_design_scores_gemma":[0.053652357,0.007444264,0.09192016,0.00018208846,0.0030027556,0.00009388188,0.017194778,0.004916009,0.802582,0.0044175535,0.013357265,0.0012368886],"about_ca_topic_score_codex":0.00027542745,"about_ca_topic_score_gemma":0.00076896854,"teacher_disagreement_score":0.09585046,"about_ca_system_score_codex":0.00005193928,"about_ca_system_score_gemma":0.0004107539,"threshold_uncertainty_score":0.5272688},"labels":[],"label_agreement":null},{"id":"W4389487695","doi":"10.1016/j.iotech.2023.100587","title":"115TiP MDT-BRIDGE: A phase II study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Genentech; LEO Pharma; Aptitude Health; European Society for Medical Oncology; Novocure; Regeneron Pharmaceuticals; Gilead Sciences; Ipsen; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Neoadjuvant therapy; Internal medicine; Durvalumab; Oncology; Stage (stratigraphy); Chemotherapy; Radiology; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.026196427080774427,"score_gpt":0.35465462112259377,"score_spread":0.32845819404181936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389487695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891118,0.0007545663,0.00018686499,0.0064738463,0.000059796414,0.0028167602,0.00004928015,0.00047990849,0.00006722],"genre_scores_gemma":[0.99327874,0.0022191724,0.0015661258,0.00034885015,0.000022972707,0.0008599836,0.00015275892,0.00009160405,0.0014598157],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972082,0.00015181137,0.0009045836,0.0007552671,0.0003270838,0.00065308326],"domain_scores_gemma":[0.99795735,0.0004286183,0.00042418434,0.00083610317,0.00022347577,0.00013027388],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000928574,0.00037490143,0.0014097943,0.0008827444,0.0002168474,0.000017176468,0.00025688313,0.00034511526,0.0002706915],"category_scores_gemma":[0.0004911989,0.00027124953,0.00004537799,0.0019304513,0.0007768781,0.00012578454,0.00019793588,0.0005873294,0.000002758647],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039401624,0.026532521,0.25268152,0.00045001143,0.0010101565,0.0010012038,0.0029875105,0.0000038479557,0.1949484,0.00017069062,0.076722786,0.40408972],"study_design_scores_gemma":[0.35024622,0.16057946,0.0629328,0.002030266,0.000847036,0.0013991628,0.010884198,0.0070781955,0.124874406,0.00051981205,0.275728,0.0028804715],"about_ca_topic_score_codex":0.00064663216,"about_ca_topic_score_gemma":0.00037934622,"teacher_disagreement_score":0.40120924,"about_ca_system_score_codex":0.00020050761,"about_ca_system_score_gemma":0.00045500978,"threshold_uncertainty_score":0.99997395},"labels":[],"label_agreement":null},{"id":"W4389487916","doi":"10.1016/j.iotech.2023.100553","title":"81P Real-world experience with docetaxel regimens in metastatic non-squamous (mNSq) non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy (PCT) and an immune checkpoint inhibitor (ICI) in the United States (US)","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"Sanofi","keywords":"Docetaxel; Medicine; Internal medicine; Discontinuation; Oncology; Lung cancer; Chemotherapy; Confidence interval; Progression-free survival; Retrospective cohort study; Response Evaluation Criteria in Solid Tumors; Performance status; Progressive disease","score_opus":0.010998413363552492,"score_gpt":0.31328312008101716,"score_spread":0.30228470671746466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389487916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99385726,0.0004672282,0.000041564617,0.0018319513,0.000059123086,0.003176507,0.000032378655,0.00023306477,0.0003009436],"genre_scores_gemma":[0.99418366,0.0006808302,0.0010139622,0.00054244266,0.00001757502,0.0027627242,0.0004575495,0.000084153864,0.00025709637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750996,0.00012938087,0.000681187,0.0006848605,0.00022995574,0.00076467526],"domain_scores_gemma":[0.9983439,0.00023964538,0.00038924994,0.00073870894,0.000201645,0.00008684519],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029541727,0.0004719746,0.0008412389,0.0014045164,0.00017703747,0.000025428282,0.00030583784,0.00024704344,0.00003032391],"category_scores_gemma":[0.00002797375,0.0003045802,0.0000493675,0.0032058498,0.00069713267,0.00012250445,0.000059455422,0.00054394774,0.0000039441866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027427725,0.0023244466,0.9517009,0.00022843055,0.00034966465,0.00079165894,0.028670257,0.0008972511,0.008926983,0.000028882288,0.00013289122,0.0032058293],"study_design_scores_gemma":[0.081556395,0.017474793,0.8104594,0.0014883867,0.0011886649,0.00012710893,0.029365513,0.009747943,0.04568284,0.000091732254,0.0016342286,0.001183018],"about_ca_topic_score_codex":0.011483026,"about_ca_topic_score_gemma":0.012321927,"teacher_disagreement_score":0.14124155,"about_ca_system_score_codex":0.00079240993,"about_ca_system_score_gemma":0.0006453821,"threshold_uncertainty_score":0.99994063},"labels":[],"label_agreement":null},{"id":"W4389488043","doi":"10.1016/j.iotech.2023.100537","title":"65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Docetaxel; Medicine; Lenvatinib; Oncology; Chemotherapy; Internal medicine; Lung cancer; Phases of clinical research; Cancer; Immunotherapy","score_opus":0.04270142033337985,"score_gpt":0.3679328438520774,"score_spread":0.32523142351869755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389488043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879132,0.003296883,0.00011381265,0.0019404311,0.0008355594,0.0051785605,0.000054660006,0.00038982567,0.00027704876],"genre_scores_gemma":[0.9949264,0.0008602545,0.0007256438,0.00030615815,0.00010308166,0.0026226921,0.00005046135,0.00010675107,0.00029854843],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997198,0.00010022684,0.0008653952,0.00077437074,0.00026531637,0.0007967271],"domain_scores_gemma":[0.99771285,0.0006392341,0.0006901867,0.0006811291,0.0001951902,0.00008140013],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063056324,0.0005054331,0.0014258315,0.0009695114,0.00025716,0.00002048339,0.0003580751,0.00052834325,0.00007846915],"category_scores_gemma":[0.00010439849,0.00045208153,0.00019225711,0.0010040961,0.00056432217,0.00008458404,0.00014022486,0.0005437829,0.0000038249814],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29053792,0.0056739547,0.0076256795,0.00092052587,0.005150198,0.00035773104,0.017990284,0.000029996289,0.38541147,0.000111273774,0.0026675921,0.28352338],"study_design_scores_gemma":[0.6193648,0.09214257,0.00325797,0.000783885,0.0018045312,0.00016766788,0.04153956,0.0029831969,0.22473189,0.000112528236,0.0119778365,0.0011335675],"about_ca_topic_score_codex":0.00024783477,"about_ca_topic_score_gemma":0.00026383318,"teacher_disagreement_score":0.32882687,"about_ca_system_score_codex":0.000536883,"about_ca_system_score_gemma":0.0007845883,"threshold_uncertainty_score":0.9997931},"labels":[],"label_agreement":null},{"id":"W4401502464","doi":"10.1016/j.iotech.2024.100726","title":"Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alethia Biotherapeutics (Canada)","funders":"Sigrid Juséliuksen Säätiö; Jane ja Aatos Erkon Säätiö; European Commission; Helsingin Yliopisto; Les Laboratories Pierre Fabre; Syöpäsäätiö; Novo Nordisk; Sanofi","keywords":"Oncolytic adenovirus; Oncolytic virus; Metastatic melanoma; Melanoma; Mucosal melanoma; Medicine; Tilt (camera); Cancer research; Tumor cells","score_opus":0.010771000269857636,"score_gpt":0.2736602485286825,"score_spread":0.26288924825882487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401502464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98697287,0.010153259,0.00006770542,0.001461159,0.000070001486,0.0009379274,0.00005021141,0.00012132532,0.00016552588],"genre_scores_gemma":[0.996284,0.00033012603,0.00173153,0.00024394837,0.000020520109,0.0011197071,0.000041596406,0.00008222458,0.0001463552],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997381,0.00042779325,0.00045092806,0.00081529724,0.00018735082,0.00073764275],"domain_scores_gemma":[0.9987957,0.00023207683,0.00011533523,0.0006684213,0.00009447585,0.00009401353],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040517704,0.0004379815,0.0005774685,0.00060056476,0.0001252221,0.000058685742,0.00028585686,0.0002824372,0.00004885834],"category_scores_gemma":[0.00007140166,0.0003298948,0.00006188672,0.00063252123,0.0008062567,0.00001534051,0.00018870598,0.00031188154,0.000030519743],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06511795,0.00044628224,0.0029335646,0.00005786876,0.0006519245,0.004889259,0.00044138572,0.000050564326,0.90265363,0.000060482478,0.000049620427,0.022647476],"study_design_scores_gemma":[0.01509913,0.20961344,0.0014846536,0.00028814722,0.00022553788,0.008195328,0.0022158215,0.0009808472,0.7334855,0.00031498887,0.027057495,0.0010390899],"about_ca_topic_score_codex":0.00011100728,"about_ca_topic_score_gemma":0.0019718572,"teacher_disagreement_score":0.20916715,"about_ca_system_score_codex":0.00057214964,"about_ca_system_score_gemma":0.0012209367,"threshold_uncertainty_score":0.9999153},"labels":[],"label_agreement":null},{"id":"W4405374307","doi":"10.1016/j.iotech.2024.100796","title":"168TiP A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Institut National Du Cancer; Eisai; Fondation ARC pour la Recherche sur le Cancer; Seagen; Astellas Pharma; NuCana; Sanofi; Exelixis; BeiGene; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Conjugate; Antibody-drug conjugate; Antibody; Medicine; Drug; Cancer research; Monoclonal antibody; Pharmacology; Immunology; Mathematics","score_opus":0.007515845738382482,"score_gpt":0.342843778635392,"score_spread":0.3353279328970095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866242,0.00058204506,0.0009780247,0.0055373358,0.0001763977,0.0048348615,0.000031053198,0.0010577951,0.00017828628],"genre_scores_gemma":[0.99029076,0.00007149248,0.007647209,0.00016943511,0.000030892836,0.0013604984,0.0002112552,0.00007657285,0.00014186415],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99682397,0.00017375634,0.0011040572,0.0008666466,0.0003810858,0.000650473],"domain_scores_gemma":[0.9980264,0.00014398807,0.000362492,0.0009945215,0.00033920686,0.00013342149],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051492965,0.00041681546,0.001095304,0.0011234953,0.00012433916,0.000015531687,0.00044998695,0.00052955054,0.00011221524],"category_scores_gemma":[0.00033094911,0.00033813514,0.00009431264,0.0017758588,0.0008693777,0.00016078063,0.00026751205,0.0011093155,0.000025861735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047729984,0.026110735,0.12375072,0.00046171446,0.00060136535,0.0012062821,0.0024790785,0.000024459963,0.7265956,0.0022420697,0.0022751892,0.10947981],"study_design_scores_gemma":[0.18132533,0.13093291,0.19689806,0.00891383,0.0026623001,0.001108995,0.011551409,0.012887666,0.3773166,0.014715866,0.057240225,0.004446801],"about_ca_topic_score_codex":0.00014518027,"about_ca_topic_score_gemma":0.000064124906,"teacher_disagreement_score":0.349279,"about_ca_system_score_codex":0.00030923175,"about_ca_system_score_gemma":0.00038337454,"threshold_uncertainty_score":0.9999071},"labels":[],"label_agreement":null},{"id":"W4405374417","doi":"10.1016/j.iotech.2024.100929","title":"176MO ORCA-010 oncolytic therapy: Inducing tumor-specific immune responses and activation of tumor microenvironment in treatment-naïve prostate cancer","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Oakville-Trafalgar Memorial Hospital; Joseph Brant Hospital; The Scarborough Hospital; Brampton Civic Hospital","funders":"Novo Nordisk; National Institute for Health and Care Research; H. Lundbeck A/S; Cancer Research UK; Gordon and Rose McAlpine Foundation for Neuroscience Research; Francis Crick Institute","keywords":"Prostate cancer; Oncolytic virus; Immune system; Tumor microenvironment; Cancer; Medicine; Cancer research; Oncology; Immune escape; Internal medicine; Immunology","score_opus":0.014793106493606751,"score_gpt":0.3085348285810627,"score_spread":0.2937417220874559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93463403,0.06303194,0.000009093812,0.001200781,0.00013645034,0.000744309,0.00006502706,0.00003946371,0.00013890042],"genre_scores_gemma":[0.97729576,0.021328013,0.00017847218,0.00005067065,0.000042514774,0.0006999845,0.000056777313,0.000040514296,0.00030729818],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837464,0.000121105244,0.0003901204,0.000583562,0.0001008885,0.00042968857],"domain_scores_gemma":[0.99930024,0.00006536365,0.0001277439,0.0004257954,0.000037037746,0.00004383552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018627141,0.00026425696,0.00038549895,0.00045965018,0.00007829697,0.000021340202,0.00018803848,0.0002620489,0.00005375691],"category_scores_gemma":[0.00003538314,0.00022986183,0.00007437471,0.00035639317,0.0005037257,0.000014219555,0.00016840223,0.00023857108,0.000007628032],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001627755,0.000293543,0.0070247096,0.000021686068,0.0002769924,0.00012995889,0.00024859206,0.0000072988123,0.8657309,0.000043164167,0.00011218558,0.12448325],"study_design_scores_gemma":[0.0029058957,0.0038839297,0.009470802,0.00010501847,0.000017965194,0.00013405697,0.00043867313,0.000013285571,0.8992495,0.00018642741,0.083396256,0.00019820785],"about_ca_topic_score_codex":0.00085799367,"about_ca_topic_score_gemma":0.00029507265,"teacher_disagreement_score":0.12428504,"about_ca_system_score_codex":0.0006350606,"about_ca_system_score_gemma":0.0005769957,"threshold_uncertainty_score":0.9373494},"labels":[],"label_agreement":null},{"id":"W4405374502","doi":"10.1016/j.iotech.2024.101027","title":"LBA3 Perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) in early-stage non-small-cell lung cancer (NSCLC): A 4-year update of KEYNOTE-671","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Chugai Pharmaceutical; EMD Serono; Berlin Institute of Health; Sun Pharma; Teijin Pharma; Medizinische Universität Innsbruck; Freie Universität Berlin; Hôpitaux Universitaires de Genève; Humboldt-Universität zu Berlin; Astellas Pharma; Eisai; Daiichi-Sankyo; Sanofi; Sungkyunkwan University; BeiGene; Mirati Therapeutics; University of Queensland; Helsinn; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Pfizer; Incyte; Universität Innsbruck; Merck KGaA; Taiho Pharmaceutical; Revolution Medicines; Regeneron Pharmaceuticals; Japan Surgical Society; Yuhan; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Amgen; Celgene; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Oncology; Stage (stratigraphy); Perioperative; Chemotherapy; Lung cancer; Internal medicine; Cancer; Radiology; Immunotherapy; Biology","score_opus":0.008401937325614091,"score_gpt":0.2975276717874244,"score_spread":0.2891257344618103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9538506,0.031387355,0.00037144154,0.0074490355,0.0009803334,0.0016425486,0.00007230524,0.0003907369,0.0038556175],"genre_scores_gemma":[0.9826371,0.010584964,0.0014091125,0.0009315917,0.00012483932,0.00056891446,0.0000335995,0.00014022538,0.0035696693],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99669546,0.00011494269,0.0010587415,0.00093811285,0.00026218494,0.0009305739],"domain_scores_gemma":[0.9983726,0.00012756136,0.0002781515,0.0009291123,0.0002011029,0.00009143542],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047597112,0.000584134,0.0014048062,0.0012563753,0.000113598384,0.00003782164,0.0006123501,0.0012840069,0.0012064788],"category_scores_gemma":[0.000039443094,0.00052552886,0.00034093083,0.0016453004,0.0009833997,0.00015069476,0.00022117811,0.0012893677,0.00005802807],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01550478,0.00075160543,0.018373124,0.00086296705,0.0014738712,0.0010278407,0.0073607108,0.000035234283,0.8715518,0.0009370385,0.0016895554,0.080431476],"study_design_scores_gemma":[0.06894076,0.006397613,0.024920778,0.0026400962,0.00067275064,0.0007967437,0.005767145,0.0052729226,0.6718852,0.00022528227,0.2106531,0.0018276236],"about_ca_topic_score_codex":0.0017257218,"about_ca_topic_score_gemma":0.00062751205,"teacher_disagreement_score":0.20896354,"about_ca_system_score_codex":0.0017959962,"about_ca_system_score_gemma":0.002252915,"threshold_uncertainty_score":0.9997196},"labels":[],"label_agreement":null},{"id":"W4405374515","doi":"10.1016/j.iotech.2024.100846","title":"103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Esophageal squamous cell carcinoma; Medicine; Chemoradiotherapy; Oncology; Basal cell; Multicenter study; Internal medicine; Carcinoma; Radiation therapy; Randomized controlled trial","score_opus":0.013252142648490887,"score_gpt":0.3187447232035502,"score_spread":0.3054925805550593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.960015,0.020793274,0.0005894751,0.0032008297,0.0005201948,0.010061387,0.000049490194,0.0013132615,0.0034571027],"genre_scores_gemma":[0.98677766,0.00013304187,0.0049274177,0.00015080105,0.00010978012,0.00401407,0.00005846992,0.00015243451,0.0036763384],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99679077,0.00009589785,0.000578442,0.0011274115,0.00035541356,0.0010520633],"domain_scores_gemma":[0.99806887,0.00034171852,0.00015129088,0.0008940083,0.000353808,0.00019028997],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025067196,0.000549728,0.0011689127,0.00096521125,0.00023152924,0.00004861141,0.00040176758,0.0003753493,0.00013766113],"category_scores_gemma":[0.000066689805,0.00043363895,0.00017736839,0.0012130485,0.0005407872,0.00013059875,0.0001408567,0.00079742493,0.000046993344],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14104114,0.08129874,0.39274827,0.002537004,0.0038806929,0.046298884,0.0052136113,0.0000499052,0.07024034,0.0049287993,0.0039658328,0.24779677],"study_design_scores_gemma":[0.19419162,0.5061646,0.04333467,0.00032356617,0.0015351223,0.0014253401,0.0033894891,0.0012506784,0.23366001,0.0016210312,0.011758625,0.0013452566],"about_ca_topic_score_codex":0.00020003867,"about_ca_topic_score_gemma":0.0010660324,"teacher_disagreement_score":0.42486584,"about_ca_system_score_codex":0.0025870868,"about_ca_system_score_gemma":0.001024273,"threshold_uncertainty_score":0.99981153},"labels":[],"label_agreement":null},{"id":"W4405374533","doi":"10.1016/j.iotech.2024.100886","title":"2O TILs and PD-L1 early dynamics in the randomized Neo-CheckRay phase II trial evaluating neo-adjuvant immuno-radiation and adenosine pathway blockade for early-stage, high risk ER+/HER2- breast cancer (BC)","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Japanese Respiratory Society; Japan Agency for Medical Research and Development","keywords":"Adenosine; Adjuvant; Blockade; Oncology; Stage (stratigraphy); Medicine; Internal medicine; Breast cancer; Randomized controlled trial; Receptor; Biology; Cancer","score_opus":0.014716830822621232,"score_gpt":0.34418831218317414,"score_spread":0.32947148136055293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94806594,0.029264767,0.00024063565,0.01538151,0.0013974588,0.0049108393,0.0003970997,0.00026261885,0.000079110105],"genre_scores_gemma":[0.98678374,0.008799524,0.0006527899,0.00036212453,0.00033841722,0.0023873837,0.00011298551,0.00008291085,0.00048014475],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963822,0.0005982318,0.0011978535,0.0007980119,0.0002971221,0.0007266283],"domain_scores_gemma":[0.9972821,0.0013577389,0.0005030677,0.0006182518,0.00017231888,0.000066511755],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032631631,0.0005042808,0.0014560838,0.0007675019,0.00045078393,0.00010348777,0.00034989955,0.0010382923,0.00012539727],"category_scores_gemma":[0.0005230275,0.0003680139,0.0002698172,0.0008818909,0.0012252297,0.00018693498,0.00015984986,0.001115911,0.000003811676],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44509342,0.00056243315,0.00088537193,0.00010886605,0.0010848505,0.000081191465,0.0024535486,0.0000031139507,0.019651666,0.0008057876,0.00016912626,0.52910066],"study_design_scores_gemma":[0.931918,0.020356894,0.008997117,0.0005406157,0.0018532277,0.00084529567,0.0022678333,0.0115722185,0.0034116337,0.0026150516,0.014854561,0.00076749944],"about_ca_topic_score_codex":0.0067451308,"about_ca_topic_score_gemma":0.0010850126,"teacher_disagreement_score":0.5283331,"about_ca_system_score_codex":0.00087084,"about_ca_system_score_gemma":0.000681272,"threshold_uncertainty_score":0.99987715},"labels":[],"label_agreement":null},{"id":"W4405374727","doi":"10.1016/j.iotech.2024.100823","title":"80P Tumor markers evolution in pts treated with TCE and association with radiologic response","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Loxo Oncology; Chugai Pharmaceutical; Novartis Pharma; Genentech; PharmaMar; Basilea Pharmaceutica; Astellas Pharma; Eisai; Eisai Canada; BeiGene; Relay Therapeutics; Seagen; Agios Pharmaceuticals; Les Laboratories Pierre Fabre; Pfizer; Incyte; Boston Pharmaceuticals; Merck KGaA; Taiho Pharmaceutical; Daiichi Sankyo Europe; Servier; Foghorn Therapeutics; Gilead Sciences; Bayer HealthCare; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Celgene; Institut National Du Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Association (psychology); Internal medicine; Medicine; Oncology; Psychology; Psychotherapist","score_opus":0.0072704661076379625,"score_gpt":0.27449455691534014,"score_spread":0.26722409080770215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705589,0.0074927155,0.00016576688,0.019594446,0.00015712902,0.0004175558,0.0000046278506,0.00053414126,0.0010747558],"genre_scores_gemma":[0.9971367,0.00027322336,0.0013072612,0.00031876971,0.000025256764,0.00016158014,0.000010871992,0.000022605213,0.000743727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982425,0.00041407242,0.0002811759,0.000477032,0.00013467437,0.00045056618],"domain_scores_gemma":[0.99850774,0.0010027346,0.00009834795,0.00024806583,0.00009084454,0.000052283824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013933287,0.00021509612,0.0005917113,0.00073687744,0.00009162538,0.000009045731,0.00008792484,0.00054018915,0.000022102557],"category_scores_gemma":[0.0012607934,0.00014489364,0.000027899965,0.000877681,0.00096699945,0.000057019817,0.000060022023,0.00083403924,0.00002417855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0102246795,0.00018336248,0.9371952,0.000103873645,0.00048300755,0.006357185,0.00031186466,0.0000029553785,0.034142006,0.00049801345,0.0018625297,0.00863531],"study_design_scores_gemma":[0.008608952,0.013000899,0.936004,0.0010433216,0.000587736,0.01327174,0.0024964337,0.0004691736,0.0020140759,0.0010218964,0.021036362,0.00044542702],"about_ca_topic_score_codex":0.00006195607,"about_ca_topic_score_gemma":0.000051347088,"teacher_disagreement_score":0.03212793,"about_ca_system_score_codex":0.00090913585,"about_ca_system_score_gemma":0.00032711442,"threshold_uncertainty_score":0.5908591},"labels":[],"label_agreement":null},{"id":"W4405374803","doi":"10.1016/j.iotech.2024.100791","title":"162P EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; AstraZeneca; Genentech; Seagen; Institut Servier; INCLIVA Instituto de Investigación Sanitaria; Menarini Group; EMD Serono; Deutschen Konsortium für Translationale Krebsforschung; Sociedad Española de Oncología Médica; PharmaMar; Novartis Farmacéutica; Daiichi Sankyo Europe; European Society for Medical Oncology; Grifols; Fundación Científica Asociación Española Contra el Cáncer; Regeneron Pharmaceuticals; Natera; BeiGene; Les Laboratories Pierre Fabre; Exelixis; Revolution Medicines; Cancer Research UK; Ribon Therapeutics; Takeda Pharmaceuticals International; Array BioPharma; Gilead Sciences; Taiho Pharmaceutical; F. Hoffmann-La Roche; HORIZON EUROPE Framework Programme; Servier; Astellas Pharma; Samsung; Eisai; FibroGen; Bristol-Myers Squibb; Eli Lilly and Company; Institut National Du Cancer; Oncode Institute; American Society of Clinical Oncology; Foundation Medicine; Sierra Oncology; European Association for Cancer Research; Sanofi; Amgen; Pfizer; Celgene","keywords":"Bevacizumab; Nivolumab; Colorectal cancer; Medicine; Oncology; Internal medicine; Metastatic melanoma; Cancer research; Chemotherapy; Immunotherapy; Cancer","score_opus":0.008630389719972233,"score_gpt":0.2672043473917885,"score_spread":0.2585739576718163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762662,0.015103449,0.00001932993,0.0022210684,0.0006417996,0.0014208221,0.00008264675,0.00047464133,0.0037700431],"genre_scores_gemma":[0.9958547,0.00049977866,0.0012209433,0.0001687282,0.0000383392,0.00061517296,0.00010495514,0.000083506566,0.0014139287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99711335,0.00009665481,0.00066539104,0.0008922256,0.0002776035,0.000954796],"domain_scores_gemma":[0.9988313,0.00018371463,0.00014075682,0.0005303727,0.00022041051,0.00009348745],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022277646,0.0005168622,0.0011988448,0.0010731706,0.00019018727,0.000040924573,0.00027689256,0.00046227127,0.000250192],"category_scores_gemma":[0.000090041314,0.00040378416,0.00014547982,0.0014757613,0.00078574114,0.00016301344,0.0002723648,0.0008352286,0.00014685879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011062879,0.0036258912,0.5973467,0.00052090356,0.0028535307,0.0061106705,0.0037041116,0.000008434145,0.012465873,0.0015971947,0.0021404724,0.35856333],"study_design_scores_gemma":[0.06008506,0.075173415,0.44080716,0.0011547524,0.0029526586,0.0037727512,0.0076745753,0.00052563875,0.05265911,0.0030433815,0.34965125,0.0025002374],"about_ca_topic_score_codex":0.0005446671,"about_ca_topic_score_gemma":0.0020821788,"teacher_disagreement_score":0.3560631,"about_ca_system_score_codex":0.002128832,"about_ca_system_score_gemma":0.00074922154,"threshold_uncertainty_score":0.9998414},"labels":[],"label_agreement":null},{"id":"W4405374842","doi":"10.1016/j.iotech.2024.100889","title":"5MO Novel radiologic phenotypes of chaotic tumor angiogenesis associated with poor ICI outcomes in NSCLC","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Syöpäsäätiö; Helsingin Yliopisto; Jane ja Aatos Erkon Säätiö; Ida Montinin Säätiö","keywords":"Angiogenesis; Phenotype; Chaotic; Medicine; Oncology; Internal medicine; Cancer research; Computer science; Biology; Genetics; Gene; Artificial intelligence","score_opus":0.018442608517930545,"score_gpt":0.27402059865668604,"score_spread":0.2555779901387555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820441,0.01034754,0.00009173504,0.004468973,0.00029784703,0.0007948118,0.000025508269,0.00047705637,0.0014524496],"genre_scores_gemma":[0.9971887,0.00008918233,0.0016520268,0.00024536724,0.000023911776,0.0002106977,0.000038859715,0.00005833579,0.0004929058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791247,0.00008839267,0.0006351176,0.0005691919,0.00019613959,0.00059871835],"domain_scores_gemma":[0.99858606,0.00048060936,0.0002036885,0.000544135,0.0001280964,0.00005743513],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003446333,0.00036879894,0.0013150524,0.001281118,0.000045658257,0.00000715046,0.00029140507,0.00061849115,0.00009912848],"category_scores_gemma":[0.00041684334,0.00025968446,0.00019599656,0.0013301502,0.000691306,0.000051847797,0.00013262419,0.00045142113,0.00005007793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001193176,0.002710015,0.53362334,0.00021394271,0.0031631019,0.005489861,0.0004465832,0.000036107027,0.43012556,0.0042784107,0.00026527446,0.01845463],"study_design_scores_gemma":[0.01602091,0.018457953,0.7769913,0.0011113223,0.0021658454,0.0045201825,0.0015369371,0.0005291282,0.17216946,0.0017032785,0.0038322893,0.00096139696],"about_ca_topic_score_codex":0.00013630872,"about_ca_topic_score_gemma":0.00017120312,"teacher_disagreement_score":0.25795612,"about_ca_system_score_codex":0.0009314618,"about_ca_system_score_gemma":0.00047497023,"threshold_uncertainty_score":0.9999855},"labels":[],"label_agreement":null},{"id":"W4405374985","doi":"10.1016/j.iotech.2024.100845","title":"102P A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenvatinib; Hepatocellular carcinoma; Medicine; Oncology; Internal medicine; Second line; Line (geometry); First line; Sorafenib","score_opus":0.035857103639493786,"score_gpt":0.2980887263409522,"score_spread":0.2622316227014584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98974276,0.0033872107,0.000004179972,0.0014044094,0.00027872087,0.004336957,0.00004359153,0.00016776941,0.00063438196],"genre_scores_gemma":[0.9975584,0.00014483434,0.00026158072,0.000017012599,0.00006278142,0.0010420001,0.000045668025,0.000073720694,0.0007939736],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973235,0.00020445095,0.0010228892,0.000626881,0.0003689727,0.00045330852],"domain_scores_gemma":[0.99756587,0.0004430743,0.00043326762,0.0012399164,0.0002472981,0.000070599526],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025826783,0.00047159108,0.0013938211,0.0009148853,0.00010970558,0.000007064619,0.00029284778,0.000461532,0.00024840032],"category_scores_gemma":[0.00006146189,0.00027620376,0.0002787985,0.0016647306,0.00065628515,0.000049393824,0.00017751261,0.00037729647,0.000009441033],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010679844,0.011632054,0.93940103,0.00043210122,0.0011404426,0.0008872969,0.001636781,0.0000028135985,0.021268224,0.00022444817,0.000056134646,0.012638809],"study_design_scores_gemma":[0.024372485,0.15128188,0.13279644,0.0012460194,0.0018073337,0.0001302986,0.0007551555,0.00063626806,0.6807835,0.00011356706,0.0057212254,0.00035580772],"about_ca_topic_score_codex":0.0003502093,"about_ca_topic_score_gemma":0.0014951644,"teacher_disagreement_score":0.8066046,"about_ca_system_score_codex":0.00039779703,"about_ca_system_score_gemma":0.00041759218,"threshold_uncertainty_score":0.999969},"labels":[],"label_agreement":null},{"id":"W4405374998","doi":"10.1016/j.iotech.2024.100749","title":"120MO Inupadenant combined with chemotherapy in patients with non-squamous NSCLC progressing on or after immune checkpoint inhibitor therapy: Results from dose-finding part of the A2A-005 trial","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Brampton Civic Hospital","funders":"","keywords":"Medicine; Oncology; Chemotherapy; Internal medicine; Immune checkpoint; Immune system; Immunotherapy; Immunology; Cancer","score_opus":0.012900915253423132,"score_gpt":0.2756339601567856,"score_spread":0.26273304490336247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850742,0.002128243,0.000005973027,0.0078759445,0.0011149641,0.0033122916,0.00004588827,0.0002164441,0.00022604542],"genre_scores_gemma":[0.9978413,0.00025503803,0.00038634907,0.00045678217,0.00015415586,0.00059223827,0.000046670713,0.00010264091,0.00016481221],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968365,0.00015697039,0.0011827615,0.0007612402,0.0004284193,0.0006341292],"domain_scores_gemma":[0.9979235,0.0003183671,0.00052335416,0.0010757435,0.00011212428,0.000046945464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005615745,0.0005039791,0.0010453414,0.0006208147,0.0001241115,0.00004506138,0.00043992265,0.00079232606,0.00010251972],"category_scores_gemma":[0.00009746202,0.00025884548,0.00019711153,0.0014588216,0.0011305609,0.00012976002,0.00011082441,0.0009977422,0.0000068691406],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80108917,0.0021043038,0.009345733,0.000051163977,0.000793136,0.00020489552,0.0015799048,0.0000012167127,0.029247042,0.000013165947,0.00014273783,0.15542755],"study_design_scores_gemma":[0.51788604,0.0735526,0.16620405,0.0060225953,0.0002726664,0.00009871741,0.0011199513,0.00004715142,0.2101209,0.00013213098,0.023645222,0.0008979644],"about_ca_topic_score_codex":0.00018844026,"about_ca_topic_score_gemma":0.00019709155,"teacher_disagreement_score":0.2832031,"about_ca_system_score_codex":0.0006580031,"about_ca_system_score_gemma":0.00087075133,"threshold_uncertainty_score":0.99998635},"labels":[],"label_agreement":null},{"id":"W4405375041","doi":"10.1016/j.iotech.2024.100746","title":"117O Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I/II non-small cell lung cancer (NSCLC): The randomized, double-blind, phase III KEYNOTE-867 study","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Stage (stratigraphy); Oncology; Medical physics; Internal medicine; Cancer; Immunotherapy; Biology","score_opus":0.017121381715622202,"score_gpt":0.3587965159867576,"score_spread":0.3416751342711354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405375041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92506194,0.040664952,0.0018819642,0.010761688,0.0014367187,0.01845328,0.00007131457,0.0007497063,0.0009184049],"genre_scores_gemma":[0.9683782,0.003934121,0.00046155,0.0005331371,0.00032743366,0.022190752,0.00007013683,0.00019603815,0.0039086565],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959817,0.000269329,0.001037048,0.0012503653,0.00036095304,0.0011005936],"domain_scores_gemma":[0.99632734,0.0012537816,0.00043800884,0.0014671342,0.00036582784,0.0001479165],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009073637,0.0007982142,0.0021961534,0.0008850752,0.0005945308,0.00010226521,0.0006845262,0.0007238592,0.00042295994],"category_scores_gemma":[0.00005175178,0.0004772136,0.00044408155,0.0012583211,0.0007793105,0.0001441175,0.00022233084,0.0011149637,0.000014660655],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9305453,0.01022023,0.005467124,0.00075112213,0.015783077,0.00162709,0.0058121453,0.00005234269,0.008318468,0.001101473,0.005463334,0.014858338],"study_design_scores_gemma":[0.9280694,0.017578935,0.00018856605,0.00042538796,0.005942056,0.0003926281,0.0016894379,0.0022487359,0.009560136,0.000062017,0.033245344,0.0005973654],"about_ca_topic_score_codex":0.0011201461,"about_ca_topic_score_gemma":0.0010058989,"teacher_disagreement_score":0.043316204,"about_ca_system_score_codex":0.0024523444,"about_ca_system_score_gemma":0.0019796053,"threshold_uncertainty_score":0.99976796},"labels":[],"label_agreement":null},{"id":"W4405375144","doi":"10.1016/j.iotech.2024.100750","title":"121MO Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: Final analysis from the randomized part 2 of the phase I/II CA027-002 study","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; PharmaMar; European Society for Medical Oncology","keywords":"Nivolumab; Ipilimumab; Medicine; Metastatic melanoma; Internal medicine; Melanoma; Oncology; Cancer research; Immunotherapy; Cancer","score_opus":0.008657859952414042,"score_gpt":0.2774406519264998,"score_spread":0.2687827919740858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405375144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896531,0.0030458174,0.000079164296,0.0032607294,0.00039522527,0.0031874157,0.000053991007,0.000119713804,0.00020485253],"genre_scores_gemma":[0.9985675,0.00027420413,0.00013449232,0.00014558382,0.000019901285,0.00057368434,0.000083308056,0.000037921352,0.0001633964],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99693644,0.0005634896,0.0009990287,0.0006499258,0.00039575784,0.0004553576],"domain_scores_gemma":[0.99776137,0.00058373535,0.00043428259,0.0010120905,0.00018050734,0.000028017335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093123905,0.0003755923,0.001661643,0.0009428537,0.00017424881,0.00001788176,0.0005633139,0.00041050353,0.0001457919],"category_scores_gemma":[0.00014280349,0.0002049609,0.0002466351,0.0037403808,0.0013130399,0.00012346229,0.00018759488,0.0008224278,0.0000036450328],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51140743,0.013228859,0.3235366,0.00007118074,0.0108641125,0.00035865026,0.007967453,0.00020417642,0.0053844415,0.00033396983,0.00029753233,0.12634557],"study_design_scores_gemma":[0.8140933,0.02113009,0.14566065,0.00054523954,0.0036322807,0.000051791623,0.006122132,0.0013651956,0.0028458168,0.00026627613,0.0038123068,0.0004749108],"about_ca_topic_score_codex":0.0016522892,"about_ca_topic_score_gemma":0.006222238,"teacher_disagreement_score":0.30268586,"about_ca_system_score_codex":0.0008154055,"about_ca_system_score_gemma":0.00061028474,"threshold_uncertainty_score":0.8358063},"labels":[],"label_agreement":null},{"id":"W4407087806","doi":"10.1016/j.iotech.2025.101042","title":"Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Celgene; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Stage (stratigraphy); Meta-analysis; Overall survival; Correlation; Melanoma; Oncology; Internal medicine; Survival analysis; Medicine; Biology; Mathematics; Cancer research","score_opus":0.07049526614308026,"score_gpt":0.3109782898953646,"score_spread":0.2404830237522843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407087806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95462465,0.01119838,0.0010371793,0.01279692,0.0008398838,0.0010869505,0.00009257749,0.00020903796,0.018114416],"genre_scores_gemma":[0.9927712,0.0019482509,0.00068340154,0.00023146601,0.00001927297,0.00020383138,0.000051340096,0.000015028494,0.0040761917],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979236,0.00011419592,0.00081607536,0.0005778429,0.00022983483,0.0003384165],"domain_scores_gemma":[0.9983625,0.0002718916,0.0003256805,0.000816396,0.00016281844,0.0000607119],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007039182,0.00026599655,0.0015479674,0.0019629316,0.00010011167,0.000008641941,0.0003010114,0.00046082004,0.00019343807],"category_scores_gemma":[0.00027758692,0.00025501326,0.00023847565,0.000635388,0.00018598158,0.00006703721,0.00077265286,0.00037262455,0.0000016770797],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049084066,0.0026709535,0.054683834,0.0003777705,0.19458641,0.0007140423,0.006535223,0.00045396178,0.021741984,0.124335945,0.0004562545,0.5885352],"study_design_scores_gemma":[0.047828276,0.02383979,0.29051188,0.00043364134,0.28734928,0.000181257,0.07824183,0.008894076,0.014286874,0.053138617,0.19231845,0.0029760266],"about_ca_topic_score_codex":0.0010425368,"about_ca_topic_score_gemma":0.0051915506,"teacher_disagreement_score":0.5855592,"about_ca_system_score_codex":0.00023560257,"about_ca_system_score_gemma":0.00010910997,"threshold_uncertainty_score":0.9999902},"labels":[],"label_agreement":null},{"id":"W7117291323","doi":"10.1016/j.iotech.2025.101225","title":"141P Clinical study of camrelizumab combined with SOX in adjuvant therapy for gastric or gastroesophageal junction adenocarcinoma: Interim report","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Jonsson Comprehensive Cancer Center; University of Colorado Denver; University of Pittsburgh; Medical Center, University of Pittsburgh; Vanderbilt University Medical Center; McGill University Health Centre; McGill University; Northwestern University; University of Texas MD Anderson Cancer Center; School of Medicine, Stanford University; Vanderbilt University; Moffitt Cancer Center; Ohio State University","keywords":"Clinical study; Gastroesophageal Junction; Adjuvant therapy; Clinical trial; Adjuvant; Interim; Interim analysis","score_opus":0.03616686054081508,"score_gpt":0.384055794376691,"score_spread":0.34788893383587594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117291323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903341,0.00078973547,0.0014742773,0.0026875518,0.0009559845,0.0032088254,0.0000024272542,0.00018535322,0.00036176687],"genre_scores_gemma":[0.99588835,0.00018697933,0.0015039296,0.0002822653,0.000049395996,0.00069780555,0.000025874464,0.000027872213,0.0013375328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734604,0.00011114608,0.0013087181,0.00060960674,0.00016163112,0.00046286394],"domain_scores_gemma":[0.9981774,0.0002503239,0.000505743,0.00078463485,0.0002422712,0.000039644234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006963458,0.0002795165,0.0013335544,0.0013549092,0.000069729824,0.0000067352307,0.00032410797,0.000405592,0.000050172934],"category_scores_gemma":[0.0003378506,0.00020390279,0.00012206664,0.0014758025,0.00038967878,0.000054584416,0.0001987347,0.0005506924,0.0000022162324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02729008,0.0036453123,0.8907109,0.00006534924,0.0006629932,0.001347234,0.00015785733,0.000003959629,0.00028791162,0.00016248245,0.0020699447,0.07359596],"study_design_scores_gemma":[0.061452955,0.08204379,0.84251565,0.0001156646,0.0005246263,0.0008029537,0.006576852,0.000058037305,0.00046071454,0.0001920013,0.0050771893,0.00017954603],"about_ca_topic_score_codex":0.00015556932,"about_ca_topic_score_gemma":0.0006805374,"teacher_disagreement_score":0.07839848,"about_ca_system_score_codex":0.00041318467,"about_ca_system_score_gemma":0.0007038353,"threshold_uncertainty_score":0.8314915},"labels":[],"label_agreement":null},{"id":"W7117293508","doi":"10.1016/j.iotech.2025.101116","title":"33P High-dimensional spatial profiling of the tumor immune microenvironment (TIME) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) reveals predictive biomarkers of immunotherapy","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Single-cell and spatial transcriptomics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Head and neck squamous-cell carcinoma; Immunotherapy; Profiling (computer programming); Tumor microenvironment; Immune system; Head and neck; Basal cell; Head and neck cancer","score_opus":0.00478656131430803,"score_gpt":0.22246178456069884,"score_spread":0.21767522324639083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117293508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98723817,0.010626795,0.00027070765,0.00043349297,0.0004190778,0.0008044398,0.00007450235,0.000014854672,0.0001179752],"genre_scores_gemma":[0.9971957,0.00023130867,0.0022265348,0.00009987778,0.000013216091,0.00007532045,0.00005033388,0.000025679517,0.00008202666],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980011,0.0002403989,0.0008073475,0.00047525438,0.0001123681,0.00036350297],"domain_scores_gemma":[0.99882245,0.000078336314,0.00039892693,0.0005948484,0.00008173426,0.000023723067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003189528,0.00027986127,0.0005998795,0.00028599924,0.00008969318,0.0000042601214,0.0004733526,0.0003775549,0.000016386935],"category_scores_gemma":[0.00008823703,0.00024187341,0.00014009874,0.00032174372,0.0009936988,0.0000055922865,0.0003144176,0.00030729384,0.0000011509865],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015999984,0.00061915367,0.051475484,0.000083621046,0.00012430272,0.0000066722605,0.0000655803,0.00004227885,0.94090295,0.000045446242,0.000042380547,0.00499214],"study_design_scores_gemma":[0.004929598,0.0021297154,0.055353682,0.000099055826,0.00006996439,0.000034346307,0.00013874682,0.00019621568,0.9361458,0.00041030085,0.00030502642,0.0001875465],"about_ca_topic_score_codex":0.00035333636,"about_ca_topic_score_gemma":0.00008726293,"teacher_disagreement_score":0.010395486,"about_ca_system_score_codex":0.000111310095,"about_ca_system_score_gemma":0.000265363,"threshold_uncertainty_score":0.9863311},"labels":[],"label_agreement":null},{"id":"W7117296119","doi":"10.1016/j.iotech.2025.101450","title":"251P Final results of the FAK-PD1 phase I/IIA study of FAK (defactinib) and PD-1 (pembrolizumab) inhibition in advanced solid tumours","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"NIH Clinical Center; University of California, San Diego; Genentech; Sierra Oncology; Ipsen; Servier; Weill Cornell Medical College; National Institute for Health and Care Research; Seagen; Sidney Kimmel Comprehensive Cancer Center; Pfizer; Moderna; NuCana; Incyte; Boston Pharmaceuticals; Cancer Research UK; Verastem Oncology; Amgen; Barbara Ann Karmanos Cancer Institute; BeiGene; Les Laboratories Pierre Fabre; Moffitt Cancer Center; Sanofi; Exelixis; Astellas Pharma; Eisai; Thomas Jefferson University; Johns Hopkins University; Celgene; Institut National Du Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Phase (matter); Cancer; Solid tumor; Cytotoxicity","score_opus":0.02047705227220095,"score_gpt":0.385868474467102,"score_spread":0.36539142219490106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117296119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99020284,0.0006929335,0.0000346344,0.0042059137,0.00016856428,0.0015833103,0.000017882734,0.000067247776,0.0030266827],"genre_scores_gemma":[0.99865663,0.0002233197,0.00025274948,0.00010173714,0.000008718085,0.00013471469,0.000011682217,0.00001941969,0.00059100013],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974751,0.00029730477,0.001002712,0.0005088039,0.00027140905,0.00044468782],"domain_scores_gemma":[0.9980329,0.00036816133,0.0003880251,0.00088601874,0.00028270957,0.000042132328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056787266,0.00022505492,0.0008458476,0.0012157053,0.00009667034,0.0000042642077,0.00030873832,0.0005265932,0.00003334193],"category_scores_gemma":[0.0015335693,0.00018282249,0.00008111332,0.0015485735,0.000947697,0.00005108942,0.0006470519,0.0009341067,0.0000040255136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01015936,0.004452121,0.012462723,0.00012435345,0.00012744743,0.00027059403,0.000714033,0.000029280469,0.9100993,0.00037919267,0.0004020024,0.06077955],"study_design_scores_gemma":[0.07735017,0.014850712,0.079034,0.00047366295,0.00019226025,0.00038400432,0.008041905,0.00023650614,0.8131578,0.0014671559,0.0045610564,0.00025078704],"about_ca_topic_score_codex":0.00015176085,"about_ca_topic_score_gemma":0.0003313543,"teacher_disagreement_score":0.09694156,"about_ca_system_score_codex":0.0002540742,"about_ca_system_score_gemma":0.0005161129,"threshold_uncertainty_score":0.74552846},"labels":[],"label_agreement":null},{"id":"W7117298964","doi":"10.1016/j.iotech.2025.101461","title":"262P EGFR mutations (EGFR+) or ALK rearrangements (ALK+) in the BR31 trial of adjuvant durvalumab (D) v placebo (P)","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Cancer Society; Dalhousie University; University of Ottawa","funders":"","keywords":"Durvalumab; Placebo; Adjuvant; Mutation; Clinical trial","score_opus":0.01786102216622019,"score_gpt":0.3937564791857949,"score_spread":0.3758954570195747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117298964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86061466,0.0026628054,0.0003075606,0.05210539,0.0020517237,0.0050070784,0.00006607618,0.00028447952,0.076900244],"genre_scores_gemma":[0.99261355,0.00038104897,0.0016006653,0.00080316165,0.00005316673,0.0013675722,0.0000981218,0.000021970542,0.0030607327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981196,0.00019127897,0.00072197046,0.00037075928,0.00019614148,0.0004002683],"domain_scores_gemma":[0.9982532,0.00055267406,0.00024147735,0.0007608936,0.00016254588,0.000029200357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044340227,0.00022223388,0.00067255256,0.0008481463,0.00016517325,0.0000095098385,0.0004070332,0.0004916962,0.00023027314],"category_scores_gemma":[0.0006489678,0.00015066341,0.000121593126,0.0012883049,0.0005704977,0.00006714294,0.00011647215,0.00044466447,0.000035942394],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12961422,0.015132591,0.021789888,0.00046412862,0.0060474677,0.0018254538,0.012567137,0.00006977289,0.037641566,0.04771216,0.0333566,0.693779],"study_design_scores_gemma":[0.36428583,0.012657359,0.015449628,0.0005170032,0.0028668423,0.00053787674,0.023939086,0.000103529346,0.0073483004,0.009187351,0.56261384,0.000493369],"about_ca_topic_score_codex":0.00035972786,"about_ca_topic_score_gemma":0.0008505776,"teacher_disagreement_score":0.69328564,"about_ca_system_score_codex":0.0006202758,"about_ca_system_score_gemma":0.0011329245,"threshold_uncertainty_score":0.6143876},"labels":[],"label_agreement":null},{"id":"W7117304384","doi":"10.1016/j.iotech.2025.101199","title":"114P Exploring the role of FES kinase in natural killer cells to enhance immunotherapy","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Immunotherapy; Kinase; Immune system; Natural killer cell; Cancer immunotherapy; Tyrosine kinase","score_opus":0.006114528020794343,"score_gpt":0.2639369299625833,"score_spread":0.25782240194178896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117304384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94590724,0.022469133,0.0001646309,0.004523468,0.020458099,0.00072903134,0.00000192348,0.00023833102,0.005508144],"genre_scores_gemma":[0.9855466,0.0008883482,0.00015493798,0.00081314053,0.000017042817,0.00043731707,0.000015950562,0.000023373046,0.012103296],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978564,0.000301769,0.0007590487,0.00045652987,0.00004112757,0.0005851438],"domain_scores_gemma":[0.9983965,0.00037942186,0.00022772876,0.00082044466,0.00016596052,0.000009937449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042499806,0.00029536168,0.0005896048,0.0011122432,0.0002359806,0.000011016661,0.00084289437,0.000586688,0.00041416765],"category_scores_gemma":[0.0001900197,0.0002395524,0.00014659716,0.0011648384,0.0005596268,0.00015105036,0.00032559747,0.001094486,0.00041602924],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006551312,0.00021404884,0.00063515734,0.0000065785166,0.00016780118,0.0000033037434,0.0006163558,0.000010454337,0.80589324,0.0029016396,0.0026217338,0.18627456],"study_design_scores_gemma":[0.00059332623,0.00027321768,0.0013443076,0.0000434318,0.000012843735,0.000020320549,0.002636516,0.000003094013,0.5709966,0.0005185508,0.42343274,0.00012509605],"about_ca_topic_score_codex":0.00030523434,"about_ca_topic_score_gemma":0.00014082277,"teacher_disagreement_score":0.420811,"about_ca_system_score_codex":0.00029531325,"about_ca_system_score_gemma":0.00015012952,"threshold_uncertainty_score":0.97686636},"labels":[],"label_agreement":null},{"id":"W7117306831","doi":"10.1016/j.iotech.2025.101226","title":"142P Infusion time of adjuvant PD-1 therapy in high-risk resectable melanoma: Accounting for distance from clinic, scheduling changes over time, and appropriately adjusting p-values in SWOG S1404","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Merck; Bristol-Myers Squibb","keywords":"Scheduling (production processes); Adjuvant; Adjuvant therapy; Continuous infusion","score_opus":0.010780104697606567,"score_gpt":0.2866931739268872,"score_spread":0.27591306922928066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117306831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98986846,0.0055345558,0.0003455519,0.0015716037,0.0003628659,0.0013398469,0.000027176915,0.0001793981,0.0007705485],"genre_scores_gemma":[0.9898275,0.0026693651,0.00599435,0.00023573644,0.0000659459,0.00022354444,0.000036436708,0.00003431299,0.0009127889],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979408,0.00012321402,0.0007664305,0.00058294565,0.00012561349,0.00046103622],"domain_scores_gemma":[0.9981881,0.0007428156,0.00045111417,0.00047237694,0.000118269236,0.000027367772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009491389,0.00025527066,0.0009863393,0.0010879779,0.000119418524,0.000014045348,0.00023824834,0.0006924423,0.00013039446],"category_scores_gemma":[0.0010663776,0.00024221092,0.000063972926,0.0007783434,0.0002663647,0.00006956906,0.00031538415,0.00058054813,0.000013066167],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059575695,0.00075361907,0.13636047,0.00024375698,0.0004050974,0.00013650228,0.00088313053,0.0000625733,0.3684234,0.00049146113,0.00032974483,0.48595268],"study_design_scores_gemma":[0.09550269,0.02254778,0.43489513,0.007083962,0.0013704089,0.00029855006,0.01223277,0.06753902,0.23559204,0.034563616,0.08559752,0.0027765199],"about_ca_topic_score_codex":0.0009981842,"about_ca_topic_score_gemma":0.0011032865,"teacher_disagreement_score":0.48317614,"about_ca_system_score_codex":0.0002791113,"about_ca_system_score_gemma":0.00013537596,"threshold_uncertainty_score":0.9877075},"labels":[],"label_agreement":null},{"id":"W7117306841","doi":"10.1016/j.iotech.2025.101399","title":"402P TMEM33 loss enhances CD8+ T cell functionality and tumour control","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"T cell; Cytotoxic T cell; Immune system; T lymphocyte; Cell","score_opus":0.006170921108255087,"score_gpt":0.28137488002997735,"score_spread":0.2752039589217223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117306841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9301664,0.021355433,0.0011002071,0.031890936,0.0012500915,0.0006786098,0.00001940486,0.00039503528,0.013143873],"genre_scores_gemma":[0.99185497,0.0014584201,0.00040555128,0.0031954888,0.00006923207,0.00016465096,0.000013066091,0.000016012502,0.0028226129],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843514,0.00008575983,0.00047320305,0.00046856957,0.000114382274,0.00042292435],"domain_scores_gemma":[0.99896616,0.00021878838,0.00016684725,0.00045061068,0.00015288021,0.000044736607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040017007,0.00024259751,0.0006345022,0.0004661756,0.00019757183,0.000013121156,0.0002145889,0.00070920476,0.00031196815],"category_scores_gemma":[0.000104406274,0.00021483195,0.00012347224,0.00058835046,0.0012924058,0.00006088508,0.00010497674,0.0004811604,0.000035176494],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004382222,0.00046113975,0.030876553,0.00011013343,0.0006021964,0.00010725708,0.000066660024,4.7462171e-7,0.88473064,0.0029830884,0.0047557177,0.07092391],"study_design_scores_gemma":[0.020702332,0.0027799855,0.06511848,0.00014737307,0.0004871635,0.00078919646,0.0009891632,0.000035422716,0.2785891,0.007435215,0.6224901,0.0004364222],"about_ca_topic_score_codex":0.000088184,"about_ca_topic_score_gemma":0.00006601346,"teacher_disagreement_score":0.61773443,"about_ca_system_score_codex":0.00029734834,"about_ca_system_score_gemma":0.00045799112,"threshold_uncertainty_score":0.8760593},"labels":[],"label_agreement":null},{"id":"W7117307022","doi":"10.1016/j.iotech.2025.101348","title":"351P Association of G-coupled protein receptor 65 (GPR65), a novel therapeutic target, with immune cell subsets in metastatic renal cell carcinoma (mRCC)","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Renal cell carcinoma; Immune system; Kidney cancer; Receptor; Cell; Immunotherapy; T cell; Kidney","score_opus":0.009426331137015345,"score_gpt":0.25070166207310923,"score_spread":0.24127533093609388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117307022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822763,0.0068840124,0.00071411347,0.004093566,0.00019927109,0.0026549578,0.000019911682,0.00017039753,0.0029874519],"genre_scores_gemma":[0.98325604,0.00007307398,0.012003771,0.00015527078,0.000017452938,0.0008683223,0.000082718165,0.00006167147,0.003481657],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99668247,0.00023983247,0.0011619946,0.0007038032,0.0003740818,0.00083781616],"domain_scores_gemma":[0.99740463,0.00031640785,0.00084953156,0.0009644887,0.0003980524,0.000066902794],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007831286,0.0005029716,0.001525333,0.0014452698,0.00010116916,0.000010682267,0.00045011853,0.00082062103,0.00015464264],"category_scores_gemma":[0.00016456007,0.00042243284,0.0002033884,0.0018255957,0.00039165447,0.0000886685,0.0001847953,0.00095893606,0.00004702933],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019499284,0.0025374242,0.06888941,0.00027134383,0.00036758525,0.00017718798,0.00031376997,0.000019591762,0.92347574,0.00037658698,0.000086973894,0.001534429],"study_design_scores_gemma":[0.018540476,0.005114599,0.043474123,0.00020279465,0.0006346227,0.00009164888,0.001080181,0.00024737118,0.92684567,0.00053858606,0.002868941,0.00036100682],"about_ca_topic_score_codex":0.00041134818,"about_ca_topic_score_gemma":0.00018174843,"teacher_disagreement_score":0.02541529,"about_ca_system_score_codex":0.002278988,"about_ca_system_score_gemma":0.0013296016,"threshold_uncertainty_score":0.99982274},"labels":[],"label_agreement":null},{"id":"W7117310539","doi":"10.1016/j.iotech.2025.101097","title":"12P Stromal CD73 expression in early-stage high-risk luminal B-like breast cancer: An exploratory analysis from the randomized Neo-CheckRay trial","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Stromal cell; Exploratory analysis; Adenosine; Breast cancer; Immune system; Pathological; Randomized controlled trial; Clinical trial","score_opus":0.006197744301364331,"score_gpt":0.26985468137124136,"score_spread":0.26365693706987703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117310539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98605955,0.008407504,0.0020041738,0.0015883442,0.000895908,0.000701313,0.0001695737,0.00008516558,0.000088479545],"genre_scores_gemma":[0.9954635,0.0016549614,0.00076448324,0.00039423417,0.00043653313,0.0006973657,0.00023892739,0.0000292389,0.00032076248],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966128,0.0010536821,0.0008176115,0.0008257659,0.00015728065,0.000532868],"domain_scores_gemma":[0.99796784,0.00026254906,0.00044852367,0.0010991086,0.00016432752,0.000057676072],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009908464,0.00037600592,0.0010585312,0.00049875275,0.0002588064,0.00003395095,0.00097542617,0.0011506218,0.00014574376],"category_scores_gemma":[0.00026400972,0.0002879183,0.00033470834,0.0010084239,0.00073542993,0.000019110648,0.0005022051,0.0006869924,0.000005594538],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4206907,0.00096603535,0.0847111,0.000013908305,0.004847915,0.00013993715,0.0008340204,0.0014899106,0.4663815,0.0005713742,0.0063085454,0.013045088],"study_design_scores_gemma":[0.7292353,0.0024486643,0.02193553,0.0001402377,0.0040195584,0.00003100164,0.0053413,0.00064542016,0.18977025,0.002198582,0.04278914,0.0014450169],"about_ca_topic_score_codex":0.0030111165,"about_ca_topic_score_gemma":0.0014881628,"teacher_disagreement_score":0.3085446,"about_ca_system_score_codex":0.00010789758,"about_ca_system_score_gemma":0.00042882434,"threshold_uncertainty_score":0.9999573},"labels":[],"label_agreement":null},{"id":"W7117311906","doi":"10.1016/j.iotech.2025.101202","title":"117eP In vitro assessment of an EphA2-targeting CAR-T cell therapy for NSCLC","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"In vitro; Radiation therapy; Cell; Cancer therapy; Cancer; Cell therapy","score_opus":0.016533222373132594,"score_gpt":0.38570954537494284,"score_spread":0.36917632300181025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117311906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97676665,0.003793592,0.00092327927,0.0048723184,0.00046768456,0.002218661,0.000015892565,0.00020353215,0.010738382],"genre_scores_gemma":[0.9826821,0.0007099387,0.013606397,0.00042709627,0.000057848094,0.0007128812,0.0000701089,0.000047555597,0.0016860567],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975818,0.00020606015,0.0007450049,0.0005525969,0.00019389937,0.00072067755],"domain_scores_gemma":[0.9980789,0.00050176075,0.00020472397,0.0008498998,0.00030967445,0.00005508411],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012621586,0.00025739777,0.0009825905,0.0014669632,0.0000932394,0.0000083471705,0.0005475813,0.00089271157,0.0003437459],"category_scores_gemma":[0.00016251257,0.0002458367,0.00016935302,0.001086934,0.0005264028,0.00006296124,0.00018282888,0.0008109734,0.00000374628],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001783348,0.00095357304,0.005370138,0.0000738544,0.00012473625,0.000040963063,0.00011344431,0.0000035616347,0.76973933,0.0005585441,0.00023677333,0.22100176],"study_design_scores_gemma":[0.012888544,0.0037012557,0.0029280016,0.0000534191,0.000046962083,0.00003914337,0.0014458022,0.00095991814,0.892676,0.0019574375,0.08310503,0.00019848872],"about_ca_topic_score_codex":0.00015246005,"about_ca_topic_score_gemma":0.00005042448,"teacher_disagreement_score":0.22080326,"about_ca_system_score_codex":0.00071168947,"about_ca_system_score_gemma":0.0011563607,"threshold_uncertainty_score":0.9999994},"labels":[],"label_agreement":null},{"id":"W7117312005","doi":"10.1016/j.iotech.2025.101572","title":"395P Synthetic IL-12 immunotherapy reverses immune suppression and halts metastasis in pancreatic cancer","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Immunotherapy; Pancreatic cancer; Immune system; Pancreatic ductal adenocarcinoma; Metastasis; Cytokine; Infiltration (HVAC); Tumor microenvironment","score_opus":0.016928231344369164,"score_gpt":0.3463640821661589,"score_spread":0.3294358508217897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117312005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9337994,0.04133784,0.00006646678,0.017494418,0.00056075386,0.0013729606,0.000020766398,0.00028292404,0.0050644586],"genre_scores_gemma":[0.96097594,0.027245099,0.0011665507,0.0006136368,0.000034246452,0.000835129,0.00001555124,0.00006637912,0.009047446],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971619,0.00032080198,0.0007577194,0.000707639,0.00022575741,0.0008261502],"domain_scores_gemma":[0.99797153,0.00049374724,0.00017617313,0.0011449015,0.00014635787,0.00006726763],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00076994393,0.00038013436,0.0013003272,0.0017901582,0.00017713,0.000020776513,0.00041879746,0.00089665886,0.002161692],"category_scores_gemma":[0.00039857457,0.00033631866,0.0001483326,0.0012527746,0.0011363664,0.0000946428,0.00037626855,0.001085126,0.000025762689],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018344977,0.00032208444,0.023975272,0.0001168879,0.0005082222,0.00018214001,0.00027401204,0.0000020140992,0.67196006,0.00057568855,0.00044982415,0.29979932],"study_design_scores_gemma":[0.017948141,0.0026364936,0.063185856,0.0016083232,0.00053724536,0.00096784515,0.0028437555,0.0001898182,0.4751865,0.0046093403,0.42956856,0.00071813475],"about_ca_topic_score_codex":0.0009315402,"about_ca_topic_score_gemma":0.00029661687,"teacher_disagreement_score":0.42911872,"about_ca_system_score_codex":0.000793934,"about_ca_system_score_gemma":0.0005996829,"threshold_uncertainty_score":0.99990886},"labels":[],"label_agreement":null},{"id":"W7117315492","doi":"10.1016/j.iotech.2025.101210","title":"126P Neoadjuvant (neoadj) nivolumab (N) + chemotherapy (C) in patients (pts) with resectable NSCLC: Outcomes by subsequent immunotherapy (IO) in CheckMate 816","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College; McGill University Health Centre","funders":"","keywords":"Nivolumab; Chemotherapy; Immunotherapy; Chemoimmunotherapy; Neoadjuvant therapy; MEDLINE","score_opus":0.005142110023032019,"score_gpt":0.27443932435254625,"score_spread":0.26929721432951426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117315492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96725565,0.0096400045,0.00007240554,0.016357113,0.00057049084,0.0020566464,0.000022960598,0.0003527425,0.0036719863],"genre_scores_gemma":[0.98771495,0.0031160328,0.00064785156,0.0043903864,0.000016452805,0.0006706323,0.000088231514,0.000106545274,0.003248896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99598306,0.00018206447,0.0012848692,0.00095752033,0.00034138156,0.0012510841],"domain_scores_gemma":[0.997905,0.00015428699,0.00037981648,0.0012947518,0.00019999781,0.00006611829],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006362041,0.00065246754,0.0016289442,0.0018329356,0.00015131406,0.000031580683,0.0007561306,0.0012632665,0.00036167735],"category_scores_gemma":[0.00008671473,0.00054757396,0.0002027672,0.002414639,0.0009075335,0.00018227907,0.00014913664,0.0011524019,0.000029685594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023946173,0.003122571,0.6367442,0.00007176663,0.00082999736,0.00014741767,0.0005202562,0.00000338154,0.09507343,0.00028536087,0.0037061016,0.23554932],"study_design_scores_gemma":[0.13335238,0.009217094,0.5455231,0.0010615283,0.00010367742,0.00012986736,0.0014071031,0.00005318451,0.061849695,0.0010865208,0.24497262,0.0012432087],"about_ca_topic_score_codex":0.0018457714,"about_ca_topic_score_gemma":0.001368285,"teacher_disagreement_score":0.24126652,"about_ca_system_score_codex":0.0026243974,"about_ca_system_score_gemma":0.000840112,"threshold_uncertainty_score":0.99969757},"labels":[],"label_agreement":null},{"id":"W7117316366","doi":"10.1016/j.iotech.2025.101405","title":"408P Calpain as a novel therapeutic target in breast cancer","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Calpain Protease Function and Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University","funders":"","keywords":"Breast cancer; Calpain; Cancer; Human breast; Disease","score_opus":0.0045596551760820276,"score_gpt":0.28193680031661134,"score_spread":0.2773771451405293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117316366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9122859,0.010067919,0.016579276,0.05062465,0.001859914,0.0011272031,0.000050368035,0.0002570157,0.0071477457],"genre_scores_gemma":[0.992755,0.0003897818,0.0005292237,0.0027246454,0.000076738885,0.0003873432,0.000051909057,0.000021267258,0.0030640685],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987046,0.00008935835,0.0003241815,0.0004505518,0.00006803157,0.0003632421],"domain_scores_gemma":[0.9993068,0.000023565832,0.00009920566,0.00043545524,0.000104951694,0.00003000318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002795139,0.00019624722,0.00026612898,0.00043856684,0.000100031146,0.000009591406,0.000289126,0.00095215015,0.0001713166],"category_scores_gemma":[0.000070638074,0.00018891343,0.000082820516,0.00060177525,0.00034594108,0.000004526837,0.00018797067,0.00028981108,0.000019977102],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042278448,0.00029628028,0.016753903,0.000014940182,0.00013926295,0.000007839653,0.000024024388,0.00011265627,0.92968184,0.006276868,0.0018609407,0.044408653],"study_design_scores_gemma":[0.00498143,0.0005533932,0.031163346,0.00007740186,0.00005755819,0.00034381606,0.0005346194,0.00065150484,0.17064002,0.009165324,0.7813051,0.00052649743],"about_ca_topic_score_codex":0.00015182969,"about_ca_topic_score_gemma":0.00022325499,"teacher_disagreement_score":0.77944416,"about_ca_system_score_codex":0.00018354219,"about_ca_system_score_gemma":0.00048448588,"threshold_uncertainty_score":0.7703666},"labels":[],"label_agreement":null},{"id":"W7117317538","doi":"10.1016/j.iotech.2025.101406","title":"409P Spatial profiling of tumour-infiltrating B cells reveals immune shifts in rapidly progressing cholangiocarcinoma","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Immune system; Antibody; Profiling (computer programming); Gene expression profiling; B cell; Phenotype","score_opus":0.012269400713676503,"score_gpt":0.3009349530357847,"score_spread":0.2886655523221082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117317538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96459156,0.021689236,0.0002557478,0.0045791985,0.00071655615,0.0011934587,0.000007867203,0.00025745053,0.006708946],"genre_scores_gemma":[0.9925792,0.00018709892,0.006432693,0.00026685453,0.00008635649,0.00025222613,0.000018881288,0.000036867757,0.0001398162],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970922,0.00013770013,0.001214536,0.00061256863,0.00019872715,0.0007442984],"domain_scores_gemma":[0.9983415,0.00022595964,0.00044815603,0.0007007672,0.00023608145,0.000047541398],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064631144,0.00036998393,0.0013627365,0.00136574,0.00016258993,0.000015693397,0.00041447682,0.00069544686,0.000030208257],"category_scores_gemma":[0.00037266195,0.00035711972,0.00021965915,0.0014000606,0.0007180355,0.00009725805,0.00038505447,0.0009118298,0.000009683588],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042051193,0.00030635382,0.24476747,0.00026680014,0.00023329387,0.00022368407,0.0004889926,0.000003862979,0.71078837,0.00088759506,0.00015356654,0.041459505],"study_design_scores_gemma":[0.006011869,0.0013837157,0.37112728,0.0010954295,0.00026999222,0.00014436792,0.0024030427,0.000131412,0.61473125,0.0010716441,0.001257471,0.00037248916],"about_ca_topic_score_codex":0.00025219153,"about_ca_topic_score_gemma":0.00012418558,"teacher_disagreement_score":0.12635982,"about_ca_system_score_codex":0.00042473013,"about_ca_system_score_gemma":0.0006162236,"threshold_uncertainty_score":0.99988806},"labels":[],"label_agreement":null},{"id":"W7117320530","doi":"10.1016/j.iotech.2025.101565","title":"350P Demystifying the biology behind a high neutrophil-to-lymphocyte ratio in gastroesophageal adenocarcinoma patients","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; McGill University Health Centre","funders":"","keywords":"Adenocarcinoma; Disease; Cancer; MEDLINE; Esophageal adenocarcinoma","score_opus":0.00567843413252664,"score_gpt":0.29341565284709265,"score_spread":0.287737218714566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117320530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97675776,0.0031891419,0.00027986112,0.015345525,0.0010782238,0.0019264582,0.000022748209,0.00033549537,0.0010647598],"genre_scores_gemma":[0.9934948,0.00007942594,0.0020509448,0.0030240403,0.00008184101,0.0010166081,0.000057772806,0.000042644504,0.00015190929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996798,0.00033368872,0.0009293063,0.00079679064,0.00016162169,0.0009806072],"domain_scores_gemma":[0.9980017,0.00030373826,0.00024158989,0.0010940382,0.00025205573,0.000106901716],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005083781,0.00041769995,0.00084400346,0.0016904694,0.00030408366,0.000020526251,0.0008721797,0.0010288538,0.00009229778],"category_scores_gemma":[0.00071020675,0.00034335026,0.00015111624,0.0013178978,0.0010044392,0.000074732045,0.000787597,0.0008012751,0.00011717881],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018035366,0.00051032554,0.92501837,0.00006139807,0.0003597225,0.00033425054,0.00022013791,0.000008739028,0.014662492,0.0060575735,0.0012463827,0.049717076],"study_design_scores_gemma":[0.010184874,0.0017762153,0.95619017,0.00018366177,0.00034634295,0.00015117537,0.0004106853,0.00014026387,0.013732545,0.0036925317,0.012848128,0.00034341824],"about_ca_topic_score_codex":0.000081661325,"about_ca_topic_score_gemma":0.000079213874,"teacher_disagreement_score":0.049373657,"about_ca_system_score_codex":0.0012742099,"about_ca_system_score_gemma":0.0008214711,"threshold_uncertainty_score":0.99990183},"labels":[],"label_agreement":null}]}